Lung Cancer

Tecemotide (INN; emepepimut-S (USAN); formerly known as BLP25 or EMD 531444) is a synthetic lipopeptide that is used as antigen in an investigational therapeutic cancer vaccine (formerly known as Stimuvax, L-BLP25, BLP25 liposomal vaccine, or BLP25 liposome vaccine).

Read more in the app

Cancer Caught in the Act: Scientists Reveal How One Type of Lung Cancer Can Transform Into Another

AstraZeneca unveils successes in treatment of lung cancer

Nanobubble Breakthrough: Unlocking the Power of Inhaled Therapy for Lung Cancer

How one type of lung cancer can transform into another

A type of allergy medicine might help treat lung cancer

Researchers Identify an Unexpected Predictor of Lung Cancer’s Return

Significant progress in small-cell lung cancer research

Lung cancer deaths cut in half with AstraZeneca pill

Lung Cancer Pill Halves Risk of Death in Some People

This Pill Can Halve The Risk of Death After Lung Cancer, Scientists Say

Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer

Lung cancer pill cuts risk of death by half, says ‘thrilling’ study

Just 3 Years of Air Pollution Can Increase Lung Cancer Risk, Study Warns

Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer

A Dangerous Connection: Depression Linked to Deadly Inflammation in Lung Cancer Patients

Cornell Scientists Uncover Major Mechanism Behind Lung Cancer’s Immune Evasion

Neoadjuvant Nivolumab Shows Long-Term Benefit in Lung Cancer Patients

A miniature robot for diagnosing lung cancer

A Life-Saving Breakthrough: Scientists Uncover Japanese Fruit Juice That May Help Prevent Lung Cancer

Human-Ignited Fires Caused 20,000 Premature U.S. Deaths – “Respiratory Infections, Lung Cancer, Heart Disease…”